MedPath

The Methodist Hospital Research Institute

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Heart Failure Hospital Readmissions and Physical Therapy

Completed
Conditions
Acute Heart Failure
First Posted Date
2018-05-07
Last Posted Date
2019-08-29
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
102
Registration Number
NCT03517514
Locations
🇺🇸

Houston Methodist Hospital, Houston, Texas, United States

Clinical Trial Readiness for SCA1 and SCA3

Conditions
Spinocerebellar Ataxia 3
Spinocerebellar Ataxia Type 1
First Posted Date
2018-04-04
Last Posted Date
2022-01-19
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
200
Registration Number
NCT03487367
Locations
🇺🇸

Houston Methodist Hospital, Houston, Texas, United States

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

Phase 2
Conditions
Renal Transplantation
Mesenchymal Stem Cells
Interventions
Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion
Other: Normal Saline (Placebo) Infusion
First Posted Date
2018-03-27
Last Posted Date
2022-03-09
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
24
Registration Number
NCT03478215
Locations
🇺🇸

Houston Methodist Hospital System, Houston, Texas, United States

Explore Transplant @Home Within Kaiser Permanente Southern California

Not Applicable
Active, not recruiting
Conditions
End Stage Renal Disease
Interventions
Behavioral: Patient-Guided
First Posted Date
2018-01-04
Last Posted Date
2023-12-28
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
977
Registration Number
NCT03389932
Locations
🇺🇸

Kaiser Permanente Research and Evaluation, Pasadena, California, United States

Phase Ib of L-NMMA and Pembrolizumab

Phase 1
Active, not recruiting
Conditions
Non-Small Cell Lung Cancer
DNA Repair-Deficiency Disorders
Urothelial Carcinoma Bladder
Malignant Melanoma
Classical Hodgkin Lymphoma
Head and Neck Squamous Cell Carcinoma
Interventions
Drug: L-NMMA
Drug: Pembrolizumab
First Posted Date
2017-08-02
Last Posted Date
2024-08-12
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
12
Registration Number
NCT03236935
Locations
🇺🇸

Houston Methodist Cancer Center, Houston, Texas, United States

Deep Brain Stimulation in Patients With LUTS

Completed
Conditions
Bladder Dysfunction
Neurogenic Bladder
First Posted Date
2017-06-28
Last Posted Date
2021-09-05
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
6
Registration Number
NCT03202251
Locations
🇺🇸

Houston Methodist Research Institute, Houston, Texas, United States

Prospective Cohort of Transitional Urology Patients

Recruiting
Conditions
Meningocele
Bladder Exstrophy
Spina Bifida
Cloacal Exstrophy
Myelomeningocele
Genitourinary Congenital Anomalies
First Posted Date
2017-02-23
Last Posted Date
2023-02-06
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
200
Registration Number
NCT03061084
Locations
🇺🇸

Houston Methodist Hospital, Houston, Texas, United States

SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

Phase 2
Completed
Conditions
Metastatic Non-small Cell Lung Cancer
Metastatic Triple-negative Breast Cancer
Interventions
Biological: ADV/HSV-tk
Drug: Valacyclovir
Radiation: SBRT
Drug: Pembrolizumab
First Posted Date
2016-12-28
Last Posted Date
2024-10-15
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
57
Registration Number
NCT03004183
Locations
🇺🇸

Houston Methodist Cancer Center, Houston, Texas, United States

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer

Phase 2
Completed
Conditions
Estrogen Receptor Positive Breast Cancer
Interventions
Drug: TAK-228
Drug: Tamoxifen
First Posted Date
2016-12-12
Last Posted Date
2021-09-22
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
28
Registration Number
NCT02988986
Locations
🇺🇸

Houston Methodist Hospital, Houston, Texas, United States

🇺🇸

Houston Methodist Hospital Willowbrook, Houston, Texas, United States

🇺🇸

Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Phase 1
Completed
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Drug: L-NMMA
Drug: Docetaxel
Drug: Amlodipine
Drug: Pegfilgrastim
Drug: Enteric-coated aspirin
First Posted Date
2016-07-15
Last Posted Date
2023-12-15
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
37
Registration Number
NCT02834403
Locations
🇺🇸

Houston Methodist Hospital, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy